Free Trial

ArriVent BioPharma (NASDAQ:AVBP) Sees Unusually-High Trading Volume - What's Next?

ArriVent BioPharma logo with Medical background

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) saw strong trading volume on Wednesday . 225,999 shares traded hands during mid-day trading, a decline of 9% from the previous session's volume of 247,550 shares.The stock last traded at $21.26 and had previously closed at $20.89.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Jones Trading assumed coverage on shares of ArriVent BioPharma in a research note on Tuesday, May 20th. They issued a "buy" rating and a $40.00 price target for the company. Wall Street Zen cut shares of ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a research note on Thursday, May 22nd. HC Wainwright boosted their price target on shares of ArriVent BioPharma from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Guggenheim reissued a "buy" rating and issued a $45.00 price target on shares of ArriVent BioPharma in a research note on Tuesday, June 24th. Finally, B. Riley assumed coverage on shares of ArriVent BioPharma in a research note on Thursday, March 20th. They issued a "buy" rating and a $37.00 price target for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ArriVent BioPharma presently has a consensus rating of "Moderate Buy" and an average target price of $40.00.

View Our Latest Stock Report on AVBP

ArriVent BioPharma Stock Performance

The company has a market cap of $710.03 million, a PE ratio of -5.51 and a beta of 1.20. The stock's 50 day moving average price is $21.71 and its 200-day moving average price is $22.80.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($1.24). On average, analysts anticipate that ArriVent BioPharma, Inc. will post -2.74 EPS for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVBP. Rhumbline Advisers raised its holdings in ArriVent BioPharma by 9.1% during the 4th quarter. Rhumbline Advisers now owns 36,690 shares of the company's stock valued at $977,000 after buying an additional 3,069 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in ArriVent BioPharma by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 206,379 shares of the company's stock valued at $5,498,000 after buying an additional 4,011 shares during the last quarter. Swiss National Bank bought a new stake in ArriVent BioPharma during the 4th quarter valued at $703,000. Intech Investment Management LLC bought a new stake in ArriVent BioPharma during the 4th quarter valued at $394,000. Finally, KLP Kapitalforvaltning AS bought a new stake in ArriVent BioPharma during the 4th quarter valued at $83,000. 9.48% of the stock is currently owned by institutional investors.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

Featured Stories

Should You Invest $1,000 in ArriVent BioPharma Right Now?

Before you consider ArriVent BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.

While ArriVent BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines